Retatrutide side effects: what the studies found
Real adverse event rates, clinical trial discontinuation numbers, and documented safety warnings from peer-reviewed literature.
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Safety summary: Retatrutide
- Evidence level Human trials
- FDA approvedNo
- Trial discontinuation6% (1 mg), 8% (4 mg), 13% (8 mg), and 16% (12 mg) in the Phase 2 NEJM obesity trial vs 0% on placebo.
- WADA sport statusCheck current list
In short: Adverse events in clinical trials are predominantly gastrointestinal: nausea (affecting up to 45% on the highest dose), diarrhea, vomiting, and constipation. These are mostly mild to moderate and peak during dose titration. Trials also observed a dose-dependent, transient increase in resting heart rate (peaking around week 24 and declining thereafter) and mild cutaneous sensations (hyperesthesia or allodynia). Cardiovascular outcome trials (TRIUMPH-Outcomes) are ongoing to confirm long-term safety.
Not an approved drug. Currently investigational in Phase 3 trials. No FDA-approved prescribing information exists.
Most common side effects
Reported symptoms in clinical trials and published pharmacology literature:
| Symptom | Reported rate | Clinical context & notes |
|---|---|---|
| Nausea | Up to 45% (at 12 mg dose) | Mild to moderate, peaking during titration intervals. |
| Diarrhea | 20% to 30% | Transient gastrointestinal response to dual GLP-1/GIP signaling. |
| Vomiting & constipation | 10% to 18% | Dose-dependent, decreasing once maintenance dose is reached. |
| Transient heart rate increase | Peak increase of +5 to +10 bpm | Dose-dependent increase in resting pulse peaking around 24 weeks, declining thereafter. |
| Cutaneous hyperesthesia (skin sensitivity) | 5% to 7% | Mild, localized sensitivity or tingling on the skin, resolving with time. |
Serious risks and warnings
Potential adverse reactions and biological risks identified in research:
- Arrhythmia & cardiovascular monitoring: Because glucagon receptor agonism increases cardiac chronotropy, long-term cardiovascular safety is under evaluation in Phase 3 trials.
- Unregulated compounding contamination: Because retatrutide is not FDA-approved, online versions carry high risk of incorrect dosage, unsterile vials, and heavy metals.
Contraindications
This compound should not be used in individuals with:
- Investigational substance: not approved for human use outside clinical trials
- History of medullary thyroid carcinoma (class warning)
- Active cardiovascular disease without trial monitoring
Common questions about Retatrutide safety
Why does retatrutide raise heart rate in clinical trials?
Glucagon receptors and GLP-1 receptors are present in the sinoatrial node of the heart. Dual activation produces a mild positive chronotropic effect. In Phase 2 trials, the heart rate increase peaked at approximately 24 weeks and declined toward baseline by week 48.
Is retatrutide safe to buy online?
No. Retatrutide is an unapproved investigational drug undergoing Phase 3 trials. Health Canada and medical authorities warn that online "research" vials have no regulatory quality standards, batch verification, or sterility testing.
How does retatrutide's discontinuation rate compare to tirzepatide?
In Phase 2 trials, discontinuation due to adverse events reached 16% at the top 12 mg dose, compared to approximately 6% to 7% for tirzepatide in Phase 3. Ongoing Phase 3 trials are testing more gradual titration schedules to improve tolerability.